UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) January 10, 2025

 

NASCENT BIOTECH, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-55299

 

46-5001940

(State or other jurisdiction 

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

631 US Hwy 1, Suite 407, North Palm Beach, FL

 

33408

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code (612) 961-5656

 

N/A

(Former name or former address, if changed since last report.) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

   

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading

Symbol(s)

 Name of each exchange

on which registered

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS

 

On January 10, 2025, Douglas Karas submitted his written resignation as an independent Director of the Company. Mr. Karas resignation is due to personal health issues he has been dealing with over the past 2 years.

 

ITEM 8.01. OTHER EVENTS

 

The Company received a delinquency from the OTC for the failure to file on a timely basis. On January 16, 2025, the Company elected to file the disclosure and financials for the period effected, quarter ending September 30, 2025 to meet the requirements to continue as a “pink Sheet” filer. The Company is assessing the value of the QB verses pink reporting and the cost difference.

 

On January 10, 2025, the Directors and Officers of the Company agreed to terminate the non- dilutive stock clause in their employment contacts.

 

 

2

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

NASCENT BIOTECH, INC.

 

 

 

/s/ Sean Carrick

 

Sean Carrick

 

President

 

 

 

Date: January 17, 2025

 

 

 

3

   

v3.24.4
Cover
Jan. 10, 2025
Cover [Abstract]  
Entity Registrant Name NASCENT BIOTECH, INC.
Entity Central Index Key 0001622057
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company true
Document Period End Date Jan. 10, 2025
Entity Ex Transition Period false
Entity File Number 000-55299
Entity Incorporation State Country Code NV
Entity Tax Identification Number 46-5001940
Entity Address Address Line 1 631 US Hwy 1
Entity Address Address Line 2 Suite 407
Entity Address City Or Town North Palm Beach
Entity Address State Or Province FL
Entity Address Postal Zip Code 33408
City Area Code 612
Local Phone Number 961-5656
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Nascent Biotech (CE) (USOTC:NBIO)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Nascent Biotech (CE) Charts.
Nascent Biotech (CE) (USOTC:NBIO)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Nascent Biotech (CE) Charts.